CCTG has opened the anticipated international brain cancer study CCTG CE9 (LUMOS2) - joining forces with the Australian Cooperative Trials Group for Neuro-Oncology (COGNO) to make enrollment accessible to Canadian patients.
Novel Therapeutics in Younger Patients with High-Risk AML (MM1YA-S01)
MODERN: An Integrated Phase 2/3 and Phase 3 Trial of MRD-Based Optimization of Adjuvant Therapy in Urothelial Cancer
Radiotherapy to Block (CURB2) Oligoprogression In Metastatic Non-Small-Cell Lung Cancer
Comparing Palliative Stereotactic Body Radiotherapy vs. Palliative Standard Radiotherapy in Patients with Advanced Head and Neck Cancer
The CCTG ES3 NEEDS international esophageal cancer clinical trial is now opened in Canada. The study is investigating whether delaying surgery for patients with squamous cell carcinoma of the esophagus is as good as the current treatment.
Eradicating MRD in Patients with AML prior to Stem Cell Transplant (ERASE)
VIGOR: Vorasidenib as Maintenance Treatment after First-line Chemoradiotherapy in IDH-mutant Grade 2 or 3 Astrocytoma
Botensilimab + Balstilimab or Botensilimab Alone vs Best Supportive Care as Therapy in Chemo-refractory, Advanced, Colorectal Adenocarcinoma: The BATTMAN Trial
STRIDE (durvalumab + tremelimumab) with Lenvatinib vs STRIDE Alone in Patients with Unresectable Hepatocellular Carcinoma (SLIDE-HCC)
CALMS: Combination Therapy with Luspatercept in Lower Risk MDS CTEP approval: 2024AUG27 (date of US Steering Committee Evaluation)
Lanreotide for the Prevention of Postoperative Pancreatic Fistula
The Office of Compliance and Oversight released an updated Good Clinical Practice training course, that includes Revision 2. The revised GCP training course is available for new members who have not yet trained in GCP. A GCP refresher module, including the Revision 2 updates, was created for members who have previously completed a GCP training course. GCP training will be valid for three years from the date of completion. This training is mandatory for all members conducting clinical trials per CCTG SOPs and in compliance with NIH policy.
Clinical Research Associate (CRA) Volunteer Needed for the Breast, Gastrointestinal and Gynecologic Disease Site Executive!
The Canadian Cancer Trials Group is actively seeking CRA representatives from Canadian Member sites to sit on the Breast, Gastrointestinal and Gynecologic Disease Site Committee Executives.
At ASCO 2019 the landmark ENZAMET | CCTG PR17 (NCT02446405) clinical trial demonstrated that hormone therapy with a drug called enzalutamide can improve the survival of some men with advanced, hormone‐sensitive prostate cancer. Findings, show that men with this sort of cancer who receive enzalutamide with standard treatment have a 33% improvement in survival compared to men receiving standard treatment alone.
IND238 (NCT03847649), A Phase II Study of Durvalumab Retreatment in Patients Who Discontinued Prior Checkpoint Therapy Due to Immune Related Toxicity, has been centrally activated.
In recognition of the critical role played by the CCTG throughout her professional career, Dr. Frances Shepherd has provided support for an annual travel award to recognize excellence in clinical trials and translational research within CCTG research projects.
2019 New Investigator Clinical Trials Course
Mark your calendars for the next CCTG New Investigator Clinical Trials Course (NICTC) being held August 7th to the 9th at the Donald Gordon Centre in Kingston, Ontario.
The NICTC is an important component of the group mandate to provide and facilitate investigator education and training. The major goal of this three-day course is to familiarize new investigators from across the country with the essentials of clinical trial conduct in the Canadian research environment.
Dr. Wassim Kassouf is a urologic oncologist working at the McGill University Health Center, the CCTG BL12 study chair and is currently a member of the clinical trials committee in genito-urinary diseases. Dr. Kassouf maintains that the BL13 trial will help evaluate whether combination therapy improves the disease control locally but also in terms of distant metastases and survival.
